FDA — authorised 17 April 2015
- Application: NDA205831
- Marketing authorisation holder: RHODES PHARMS
- Status: supplemented
🇺🇸 Aptensio XR in United States
FDA authorised Aptensio XR on 17 April 2015
Marketing authorisation
Other Psychiatry/Neurology approved in United States
Frequently asked questions
Is Aptensio XR approved in United States?
Yes. FDA authorised it on 17 April 2015.
Who is the marketing authorisation holder for Aptensio XR in United States?
RHODES PHARMS holds the US marketing authorisation.